糖尿病与原发性肝癌:危险因素还是致病病因?

梁静; 韩涛

doi:10.3969/j.issn.1001-5256.2017.04.037

糖尿病与原发性肝癌:危险因素还是致病病因?

DOI: 10.3969/j.issn.1001-5256.2017.04.037

梁静,
韩涛

天津市第三中心医院消化内科

详细信息

中图分类号: R735.7;R587.1
计量
- 文章访问数: 316
- HTML全文浏览量: 20
- PDF下载量: 357
- 被引次数: 0
出版历程
- 收稿日期: 2016-11-10
- 出版日期: 2017-04-20

Diabetes mellitus and primary liver cancer: risk factor or real cause?

Liang Jing,
Han Tao

Department of Gastroenterology, Tianjin Third Central Hospital

摘要

摘要: 糖尿病发病率在全球范围内普遍升高,并被认为是非病毒性肝炎患者发生肝癌的潜在病因。糖尿病是否为肝癌的致病病因及发病机制目前仍不明确。回顾了近期大样本的队列研究,证实了糖尿病增加肝癌的发病率并影响其预后。同时阐述了丙型肝炎、肥胖及非酒精性脂肪性肝病与糖尿病及肝癌之间的密切关系,分析了胰岛素抵抗及慢性炎症因子的激活可能参与了癌细胞的产生及增殖。评述了抗胰岛素抵抗的药物对肝癌发生发展的影响。认为糖尿病可能是肝癌发生的致病病因,有效控制胰岛素抵抗有助于减少糖尿病相关肝癌的发生及进展。
- 肝肿瘤 /
- 糖尿病 /
- 综述
Abstract: With an increasing prevalence all over the world, diabetes mellitus is considered as a potential cause of liver cancer in patients with non-viral hepatitis. Whether diabetes mellitus is the cause of liver cancer and related pathogenesis remain unknown. The article reviews recent large-sample cohort studies and confirms that diabetes mellitus increases the incidence rate of liver cancer and affects its prognosis. This article also investigates the association of hepatitis C, obesity, and nonalcoholic fatty liver disease with diabetes mellitus and liver cancer and finds that insulin resistance and activation of chronic inflammatory factors may be involved in the generation and proliferation of cancer cells. This article elaborates on the influence of anti-insulin resistance drugs on the development and progression of liver cancer and points out that diabetes mellitus may be the cause of liver cancer. Effective control of insulin resistance can help to reduce the development and progression of diabetes-associated liver cancer.
- liver neoplasms /
- diabetes mellitus /
- review

HTML全文

参考文献(57)

[1]El-SERAG HB.Epidemiology of viral hepatitis and hepatocellular carcinoma[J].Gastroenterology, 2012, 142 (6) :1264-1273, e1.

[2]CHEN W, ZHENG R, BAADE PD, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66 (2) :115-132.

[3]MUKHERJEE B, BHATTACHARYA S, CHAKRABORTY S, et al.Is type 2 diabetes mellitus a predisposal cause for developing hepatocellular carcinoma?[J].Curr Diabetes Rev, 2015, 11 (2) :64-70.

[4]SHAW JE, SICREE RA, ZIMMET PZ.Global estimates of the prevalence of diabetes for 2010 and 2030[J].Diabetes Res Clin Pract, 2010, 87 (1) :4-14.

[5]OKANOUE T, UMEMURA A, YASUI K, et al.Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan[J].J Gastroenterol Hepatol, 2011, 26 (Suppl 1) :153-162.

[6]GIOVANNUCCI E, HARLAN DM, ARCHER MC, et al.Diabetes and cancer:a consensus report[J].Diabetes Care, 2010, 33 (7) :1674-1685.

[7]YANG WS, VA P, BRAY F, et al.The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis:a meta-analysis of prospective cohort studies[J].PLo S One, 2011, 6 (12) :e27326.

[8]WANG C, WANG X, GONG G, et al.Increased risk of hepatocellular carcinoma in patients with diabetes mellitus:a systematic review and meta-analysis of cohort studies[J].Int J Cancer, 2012, 130 (7) :1639-1648.

[9]SCHLESINGER S, ALEKSANDROVA K, PISCHON T, et al.Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort[J].Ann Oncol, 2013, 24 (9) :2449-2455.

[10]SETIAWAN VW, HERNANDEZ BY, LU SC, et al.Diabetes and racial/ethnic differences in hepatocellular carcinoma risk:the multiethnic cohort[J].J Natl Cancer Inst, 2014, 106 (12) :dju326.

[11]YANG JD, AHMED MOHAMMED H, CVINAR JL, et al.Diabetes mellitus heightens the risk of hepatocellular carcinoma except in patients with hepatitis C cirrhosis[J].Am J Gastroenterol, 2016, 111 (11) :1573-1580.

[12]LI CI, CHEN HJ, LAI HC, et al.Hyperglycemia and chronic liver diseases on risk of hepatocellular carcinoma in Chinese patients with type 2 diabetes—National cohort of Taiwan diabetes study[J].Int J Cancer, 2015, 136 (11) :2668-2679.

[13]WANG YG, WANG P, WANG B, et al.Diabetes mellitus and poorer prognosis in hepatocellular carcinoma:a systematic review and metaanalysis[J].PLo S One, 2014, 9 (5) :e95485.

[14]ALEMN JO, EUSEBI LH, RICCIARDIELLO L, et al.Mechanisms of obesity-induced gastrointestinal neoplasia[J].Gastroenterology, 2014, 146 (2) :357-373.

[15]VANNI E, BUGIANESI E.Obesity and liver cancer[J].Clin Liver Dis, 2014, 18 (1) :191-203.

[16]CHEN Y, WANG X, WANG J, et al.Excess body weight and the risk of primary liver cancer:an updated meta-analysis of prospective studies[J].Eur J Cancer, 2012, 48 (14) :2137-2145.

[17]LIU X, XU J.Body mass index and waistline are predictors of survival for hepatocellular carcinoma after hepatectomy[J].Med Sci Monit, 2015, 21:2203-2209.

[18]VOHRA NA, KACHARE SD, VOS P, et al.The short-term effect of weight loss surgery on volumetric breast density and fibroglandular volume[J].Obes Surg, 2016.[Epub ahead of print]

[19]ASCHA MS, HANOUNEH IA, LOPEZ R, et al.The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis[J].Hepatology, 2010, 51 (6) :1972-1978.

[20]MEHTA SH, BRANCATI FL, SULKOWSKI MS, et al.Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States[J].Ann Intern Med, 2000, 133 (8) :592-599.

[21]WONG RJ, GISH RG.Metabolic manifestations and complications associated with chronic hepatitis C virus infection[J].Gastroenterol Hepatol (N Y) , 2016, 12 (5) :293-299.

[22]ROMERO-GOMEZ M, FERNANDEZ-RODRIGUEZ CM, ANDRADE RJ, et al.Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C[J].J Hepatol, 2008, 48 (5) :721-727.

[23]ARASE Y, SUZUKI F, SUZUKI Y, et al.Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C[J].Hepatology, 2009, 49 (3) :739-744.

[24]DYAL HK, AGUILAR M, BHUKET T, et al.Concurrent obesity, diabetes, and steatosis increase risk of advanced fibrosis among HCV patients:a systematic review[J].Dig Dis Sci, 2015, 60 (9) :2813-2824.

[25]DYAL HK, AGUILAR M, BARTOS G, et al.Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C virus patients:a systematic review[J].Dig Dis Sci, 2016, 61 (2) :636-645.

[26]MICHELOTTI GA, MACHADO MV, DIEHL AM.NAFLD, NASH and liver cancer[J].Nat Rev Gastroenterol Hepatol, 2013, 10 (11) :656-665.

[27]SIEGEL AB, ZHU AX.Metabolic syndrome and hepatocellular carcinoma:two growing epidemics with a potential link[J].Cancer, 2009, 115 (24) :5651-5661.

[28]BAFFY G, BRUNT EM, CALDWELL SH.Hepatocellular carcinoma in non-alcoholic fatty liver disease:an emerging menace[J].J Hepatol, 2012, 56 (6) :1384-1391.

[29]LONARDO A, BELLENTANI S, ARGO CK, et al.Epidemiological modifiers of non-alcoholic fatty liver disease:focus on high-risk groups[J].Dig Liver Dis, 2015, 47 (12) :997-1006.

[30]MOSCHEN AR, KASER S, TILG H.Non-alcoholic steatohepatitis:a microbiota-driven disease[J].Trends Endocrinol Metab, 2013, 24 (11) :537-545.

[31]SHULMAN GI.Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease[J].N Engl J Med, 2014, 371 (23) :1131-1141.

[32]SAMUEL VT, SHULMAN GI.Mechanisms for insulin resistance:common threads and missing links[J].Cell, 2012, 148 (5) :852-871.

[33]DONGIOVANNI P, RAMETTA R, MERONI M, et al.The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development-a potential therapeutic target?[J].Expert Rev Gastroenterol Hepatol, 2016, 10 (2) :229-242.

[34]GARCIA-COMPEAN D, JAQUEZ-QUINTANA JO, GONZALEZGONZALEZ JA, et al.Liver cirrhosis and diabetes:risk factors, pathophysiology, clinical implications and management[J].World J Gastroenterol, 2009, 15 (3) :280-288.

[35]ZHANG H, PELZER AM, KIANG DT, et al.Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin[J].Cancer Res, 2007, 67 (1) :391-397.

[36]MARDILOVICH K, PANKRATZ SL, SHAW LM.Expression and function of the insulin receptor substrate proteins in cancer[J].Cell Commun Signal, 2009, 7:14.

[37]YAO M, WANG L, YANG J, et al.IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo[J].Tumour Biol, 2016, 37 (11) :14677-14686.

[38]CHETTOUH H, LEQUOY M, FARTOUX L, et al.Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma[J].Liver Int, 2015, 35 (10) :2203-2217.

[39]El-SERAG HB, RUDOLPH KL.Hepatocellular carcinoma:epidemiology and molecular carcinogenesis[J].Gastroenterology, 2007, 132 (7) :2557-2576.

[40]CAPONE F, GUERRIERO E, COLONNA G, et al.The cytokinome profile in patients with hepatocellular carcinoma and type 2 diabetes[J].PLo S One, 2015, 10 (7) :e0134594.

[41]NAKAGAWA H, MAEDA S, YOSHIDA H, et al.Serum IL-6levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients:an analysis based on gender differences[J].Int J Cancer, 2009, 125 (10) :2264-2269.

[42]WONG VW, YU J, CHENG AS, et al.High serum interleukin-6level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B[J].Int J Cancer, 2009, 124 (12) :2766-2770.

[43]PARK EJ, LEE JH, YU GY, et al.Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression[J].Cell, 2010, 140 (2) :197-208.

[44]ALI KAMKAR MM, AHMAD R, ALSMADI O, et al.Insight into the impact of diabetes mellitus on the increased risk of hepatocellular carcinoma:mini-review[J].J Diabetes Metab Disord, 2014, 13:57.

[45]NAUGLER WE, SAKURAI T, KIM S, et al.Gender disparity in liver cancer due to sex differences in My D88-dependent IL-6 production[J].Science, 2007, 317 (5834) :121-124.

[46]YU H, PARDOLL D, JOVE R.STATs in cancer inflammation and immunity:a leading role for STAT3[J].Nat Rev Cancer, 2009, 9 (11) :798-809.

[47]HE G, YU GY, TEMKIN V, et al.Hepatocyte IKKbeta/NF-kappa B inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation[J].Cancer Cell, 2010, 17 (3) :286-297.

[48]TAKAHASHI H, MIZUTA T, EGUCHI Y, et al.Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C[J].J Gastroenterol, 2011, 46 (6) :790-798.

[49]MILES KA, WILLIAMS RE.Warburg revisited:imaging tumour blood flow and metabolism[J].Cancer Imaging, 2008, 8:81-86.

[50]CHOCARRO-CALVO A, GARCIA-MARTINEZ JM, ARDILAGONZALEZ S, et al.Glucose-induced beta-catenin acetylation enhances Wnt signaling in cancer[J].Mol Cell, 2013, 49 (3) :474-486.

[51]EVANS JM, DONNELLY LA, EMSLIE-SMITH AM, et al.Metformin and reduced risk of cancer in diabetic patients[J].BMJ, 2005, 330 (7503) :1304-1305.

[52]BOWKER SL, MAJUMDAR SR, VEUGELERS P, et al.Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin:response to farooki and schneider[J].Diabetes Care, 2006, 29 (8) :1990-1991.

[53]HASSAN MM, CURLEY SA, LI D, et al.Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma[J].Cancer, 2010, 116 (8) :1938-1946.

[54]STEVENS RJ, ALI R, BANKHEAD CR, et al.Cancer outcomes and all-cause mortality in adults allocated to metformin:systematic review and collaborative meta-analysis of randomised clinical trials[J].Diabetologia, 2012, 55 (10) :2593-2603.

[55]SUN G, KASHYAP SR.Cancer risk in type 2 diabetes mellitus:metabolic links and therapeutic considerations[J].J Nutr Metab, 2011, 2011:708183.

[56]GIOVANNUCCI E, HARLAN DM, ARCHER MC, et al.Diabetes and cancer:a consensus report[J].CA Cancer J Clin, 2010, 60 (4) :207-221.

[57]FUJITA K, IWAMA H, MIYOSHI H, et al.Diabetes mellitus and metformin in hepatocellular carcinoma[J].World J Gastroenterol, 2016, 22 (27) :6100-6113.

施引文献

资源附件(0)

访问统计